• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
High-Grade Glioma - Pipeline Review, H1 2013 - Product Image

High-Grade Glioma - Pipeline Review, H1 2013

  • ID: 2557599
  • May 2013
  • 42 pages
  • Global Markets Direct

High-Grade Glioma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'High-Grade Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for High-Grade Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for High-Grade Glioma. High-Grade Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for High-Grade Glioma.
- A review of the High-Grade Glioma products under development by companies and universities/research institutes READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
High-Grade Glioma Overview
Therapeutics Development
An Overview of Pipeline Products for High-Grade Glioma
High-Grade Glioma Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
High-Grade Glioma Therapeutics – Products under Development by Companies
Companies Involved in High-Grade Glioma Therapeutics Development
Boehringer Ingelheim GmbH
Genentech, Inc.
Bayer AG
Stemline Therapeutics, Inc.
Tocagen Inc
High-Grade Glioma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vocimagene amiretrorepvec + flucytosine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GDC-0084 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
High-Grade Glioma Therapeutics – Drug Profile Updates
High-Grade Glioma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for High-Grade Glioma, H1 2013
Products under Development for High-Grade Glioma – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Boehringer Ingelheim GmbH, H1 2013
Genentech, Inc., H1 2013
Stemline Therapeutics, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
High-Grade Glioma Therapeutics – Drug Profile Updates
High-Grade Glioma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for High-Grade Glioma, H1 2013
Products under Development for High-Grade Glioma – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos